Clinical Report: First 20mL Universal Plunger for Large-Volume On-Body Delivery

Overview

Datwyler has introduced the NeoFlex™ plunger, designed for 20mL cartridges, facilitating slow and controlled drug delivery for large-volume subcutaneous administration. This innovation addresses the challenges faced by manufacturers in providing high-dose therapies and enhances patient comfort during self-administration.

Background

The demand for large-volume subcutaneous (SC) delivery is increasing, particularly in oncology and immunology, where high-dose biologics are becoming routine. However, manufacturers encounter significant hurdles in developing compatible delivery systems for these therapies. The introduction of standardized, off-the-shelf components like the NeoFlex™ plunger is critical for improving patient care and streamlining the drug delivery process.

Data Highlights

No numerical or trial data available in the source material.

Key Findings

• The NeoFlex™ plunger is the first universal plunger designed for 20mL cartridges.
• It enables slow, controlled drug delivery, enhancing patient comfort for at-home administration.
• The plunger is compatible with all existing 20mL ISO cartridges on the market.
• It is covered with a non-fluorosurfactant grade fluoropolymer coating, ensuring safety and compatibility with various formulations.
• This innovation aims to reduce development complexity and costs for pharmaceutical and medical device manufacturers.

Clinical Implications

The NeoFlex™ plunger represents a significant advancement in the delivery of high-dose therapies, potentially improving patient adherence and comfort. Healthcare providers should consider the implications of this technology in enhancing self-administration practices for patients requiring large-volume injections.

Conclusion

The introduction of the NeoFlex™ plunger marks a pivotal development in large-volume drug delivery systems, supporting the growing trend of subcutaneous administration in clinical practice. This innovation is expected to facilitate better patient experiences and outcomes in the management of high-dose therapies.

References

1. Ophthalmology Management, 2003 -- IOL Inserter
2. Surgical Endoscopy, 2025 -- Assessment of Learning Curve and Insertion Depth for Veress Needle Techniques: A Comparison of Conventional and VeressPlus™ Needles
3. Retinal Physician, 2021 -- Exploring Syringe Selection for Intravitreal Injections
4. Infusion Therapy Standards of Practice, 2024 -- PubMed
5. FDA -- FDA approves atezolizumab and hyaluronidase-tqjs for subcutaneous injection
6. Surgical Endoscopy — An Innovative Mechanism for the Veress Needle That Minimizes Overshooting During Abdominal Wall Puncture
7. BD Libertas™ Wearable Injector
8. Infusion Therapy Standards of Practice, 9th Edition - PubMed
9. FDA approves atezolizumab and hyaluronidase-tqjs for subcutaneous injection | FDA